JP2007505902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505902A5 JP2007505902A5 JP2006526856A JP2006526856A JP2007505902A5 JP 2007505902 A5 JP2007505902 A5 JP 2007505902A5 JP 2006526856 A JP2006526856 A JP 2006526856A JP 2006526856 A JP2006526856 A JP 2006526856A JP 2007505902 A5 JP2007505902 A5 JP 2007505902A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- alkoxy
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- -1 R 21 Chemical compound 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000001589 carboacyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 2
- 102000016799 Leukocyte elastase Human genes 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001345 alkine derivatives Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302487A SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Novel compounds |
| PCT/SE2004/001336 WO2005026124A1 (en) | 2003-09-18 | 2004-09-15 | 2-pyridone derivatives as netrophil elastase inhibitors and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505902A JP2007505902A (ja) | 2007-03-15 |
| JP2007505902A5 true JP2007505902A5 (enExample) | 2007-11-01 |
Family
ID=29212489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526856A Pending JP2007505902A (ja) | 2003-09-18 | 2004-09-15 | 好中球エラスターゼ阻害剤としての２−ピリドン誘導体およびその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070043036A1 (enExample) |
| EP (1) | EP1663974B1 (enExample) |
| JP (1) | JP2007505902A (enExample) |
| KR (1) | KR20060096995A (enExample) |
| CN (1) | CN100439339C (enExample) |
| AR (1) | AR046083A1 (enExample) |
| AT (1) | ATE420861T1 (enExample) |
| AU (1) | AU2004272485B2 (enExample) |
| BR (1) | BRPI0414570A (enExample) |
| CA (1) | CA2538410A1 (enExample) |
| CO (1) | CO5670357A2 (enExample) |
| DE (1) | DE602004019110D1 (enExample) |
| ES (1) | ES2319300T3 (enExample) |
| IL (1) | IL173986A0 (enExample) |
| IS (1) | IS8394A (enExample) |
| MX (1) | MXPA06002723A (enExample) |
| NO (1) | NO20061700L (enExample) |
| RU (1) | RU2348617C2 (enExample) |
| SA (1) | SA04250300B1 (enExample) |
| SE (1) | SE0302487D0 (enExample) |
| TW (1) | TW200526579A (enExample) |
| UA (1) | UA84878C2 (enExample) |
| UY (1) | UY28513A1 (enExample) |
| WO (1) | WO2005026124A1 (enExample) |
| ZA (1) | ZA200602262B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| ES2600460T3 (es) * | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
| JP2009504624A (ja) | 2005-08-08 | 2009-02-05 | アージェンタ ディスカバリー リミテッド | ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用 |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| US20070104699A1 (en) * | 2005-09-29 | 2007-05-10 | University Of Alberta | Compositions for and methods of granzyme B inhibition |
| GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| TW200808763A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| EP2535330A3 (en) | 2006-10-23 | 2012-12-26 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
| SI2089364T1 (sl) | 2006-11-08 | 2013-10-30 | Bristol-Myers Squibb Company | Spojine piridinona |
| EP2217591A4 (en) | 2007-11-06 | 2011-10-26 | Astrazeneca Ab | CERTAIN 2-PYRAZINONE DERIVATIVES AND THEIR USE AS NEUTROPHILES ELASTASE INHIBITORS |
| DK2229358T3 (da) | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
| BRPI0906444B8 (pt) | 2008-01-23 | 2021-05-25 | Bristol Myers Squibb Co | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos |
| US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| CA2752693A1 (en) | 2009-02-17 | 2010-08-26 | Chiesi Farmaceutici S.P.A. | Triazolopyridine derivatives as p38 map kinase inhibitors |
| GB0902648D0 (en) | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| AU2010302420B2 (en) * | 2009-10-02 | 2013-07-04 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| WO2011071730A1 (en) * | 2009-12-08 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| CN104024241B (zh) | 2011-08-01 | 2016-01-20 | 大日本住友制药株式会社 | 尿嘧啶衍生物和其用于医学目的的用途 |
| US9458154B2 (en) | 2011-12-09 | 2016-10-04 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| MY167216A (en) | 2011-12-09 | 2018-08-14 | Chiesi Farm Spa | Kinase inhibitors |
| UA115320C2 (uk) | 2011-12-09 | 2017-10-25 | К'Єзі Фармачеутічі С.П.А. | Інгібітори кінази |
| US20140057926A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US9102624B2 (en) | 2012-08-23 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140057920A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| RU2015151886A (ru) | 2013-06-06 | 2017-06-08 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Ингибиторы киназ |
| US9221807B2 (en) * | 2014-02-21 | 2015-12-29 | Boehringer Ingelheim International Gmbh | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| JP6532599B2 (ja) | 2015-09-02 | 2019-06-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| AR107165A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
| WO2017108736A1 (en) | 2015-12-23 | 2017-06-29 | Chiesi Farmaceutici S.P.A. | N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors |
| MA44131A (fr) | 2015-12-23 | 2021-05-26 | Chiesi Farm Spa | Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk |
| JP7034942B2 (ja) | 2016-05-05 | 2022-03-14 | エフ．ホフマン－ラ ロシュ アーゲー | ピラゾール誘導体、その組成物及び治療的使用 |
| CN109890817B (zh) | 2016-09-06 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法 |
| CR20190310A (es) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
| JP2020510061A (ja) | 2017-03-14 | 2020-04-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
| CN110678467B (zh) | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| MX387969B (es) | 2017-05-22 | 2025-03-19 | Hoffmann La Roche | Composiciones y compuestos terapéuticos, y métodos para su uso. |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| EP3740488A1 (en) | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine compounds as jak inhibitors |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| CN110192947B (zh) * | 2019-05-28 | 2022-01-04 | 河南省超亚医药器械有限公司 | 一种小儿肺部热敷贴 |
| CN110192948B (zh) * | 2019-05-28 | 2022-01-04 | 河南省超亚医药器械有限公司 | 一种小儿腹部热敷贴 |
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
| PH12021552998A1 (en) | 2019-06-18 | 2023-08-14 | Hoffmann La Roche | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
| JP7672641B2 (ja) | 2019-09-17 | 2025-05-08 | メレオ バイオファーマ ４ リミテッド | 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット |
| IL297211B2 (en) | 2020-04-16 | 2025-12-01 | Mereo Biopharma 4 Ltd | Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency |
| KR20240090272A (ko) | 2021-10-20 | 2024-06-21 | 메레오 바이오파마 4 리미티드 | 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제 |
| CN114057630B (zh) * | 2021-12-23 | 2023-06-02 | 郑州大学 | 吡非尼酮衍生物及其合成方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521179A (en) * | 1991-04-18 | 1996-05-28 | Zeneca Limited | Heterocyclic amides |
| GB9207145D0 (en) * | 1991-04-18 | 1992-05-13 | Ici Plc | Heterocyclic amides |
| FR2687674B1 (fr) * | 1992-02-07 | 1995-05-19 | Roussel Uclaf | Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
| RU2140917C1 (ru) * | 1993-11-19 | 1999-11-10 | Парк, Дэвис энд Компани | Производные 5,6-дигидропирона и фармацевтическая композиция на их основе |
| RU2067579C1 (ru) * | 1994-10-07 | 1996-10-10 | Пермский фармацевтический институт | 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность |
| KR100828982B1 (ko) * | 2000-12-28 | 2008-05-14 | 시오노기세이야쿠가부시키가이샤 | 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체 |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| DE60214428T2 (de) * | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-dihydro-1, 4-diphenylpyridin-derivate |
| GB2383326A (en) * | 2001-12-20 | 2003-06-25 | Bayer Ag | Antiinflammatory dihydropyridines |
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-09-18 SE SE0302487A patent/SE0302487D0/xx unknown
-
2004
- 2004-09-13 TW TW093127678A patent/TW200526579A/zh unknown
- 2004-09-15 AU AU2004272485A patent/AU2004272485B2/en not_active Ceased
- 2004-09-15 CA CA002538410A patent/CA2538410A1/en not_active Abandoned
- 2004-09-15 UA UAA200602252A patent/UA84878C2/ru unknown
- 2004-09-15 RU RU2006112427/04A patent/RU2348617C2/ru not_active IP Right Cessation
- 2004-09-15 WO PCT/SE2004/001336 patent/WO2005026124A1/en not_active Ceased
- 2004-09-15 BR BRPI0414570-4A patent/BRPI0414570A/pt not_active IP Right Cessation
- 2004-09-15 CN CNB2004800275174A patent/CN100439339C/zh not_active Expired - Fee Related
- 2004-09-15 JP JP2006526856A patent/JP2007505902A/ja active Pending
- 2004-09-15 KR KR1020067005458A patent/KR20060096995A/ko not_active Withdrawn
- 2004-09-15 US US10/572,640 patent/US20070043036A1/en not_active Abandoned
- 2004-09-15 DE DE602004019110T patent/DE602004019110D1/de not_active Expired - Fee Related
- 2004-09-15 AT AT04775439T patent/ATE420861T1/de not_active IP Right Cessation
- 2004-09-15 MX MXPA06002723A patent/MXPA06002723A/es unknown
- 2004-09-15 EP EP04775439A patent/EP1663974B1/en not_active Expired - Lifetime
- 2004-09-15 UY UY28513A patent/UY28513A1/es unknown
- 2004-09-15 ES ES04775439T patent/ES2319300T3/es not_active Expired - Lifetime
- 2004-09-17 AR ARP040103354A patent/AR046083A1/es not_active Application Discontinuation
- 2004-09-18 SA SA4250300A patent/SA04250300B1/ar unknown
-
2006
- 2006-02-27 IL IL173986A patent/IL173986A0/en unknown
- 2006-03-15 CO CO06026211A patent/CO5670357A2/es not_active Application Discontinuation
- 2006-03-17 ZA ZA200602262A patent/ZA200602262B/xx unknown
- 2006-03-31 IS IS8394A patent/IS8394A/is unknown
- 2006-04-18 NO NO20061700A patent/NO20061700L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505902A5 (enExample) | ||
| RU2006112427A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| AU2013355130B2 (en) | Methods of synthesizing a prostacyclin analog | |
| RU2476429C2 (ru) | Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого | |
| BR112020008851A2 (pt) | composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas | |
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| CA2525841A1 (en) | Cyclohexyl sulphones as gamma-secretase inhibitors | |
| JP2017519754A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| CN1305471A (zh) | 二氢嘧啶类化合物 | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2007504128A5 (enExample) | ||
| JP2005511699A5 (enExample) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2006509015A5 (enExample) | ||
| CA2261827C (fr) | Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales | |
| CA2930574A1 (en) | Amine salts of a prostacyclin analog | |
| JP2023533003A5 (enExample) | ||
| JP2022529309A5 (enExample) | ||
| JP2013525490A5 (enExample) | ||
| JP2004525178A5 (enExample) | ||
| JP2005502636A5 (enExample) | ||
| RU2004117595A (ru) | Производные пиридина в качестве лигандов рецептора nmda | |
| JP2005536487A5 (enExample) | ||
| JP2024526191A5 (enExample) |